BEIGF — what changed in the latest 10-Q
A section-by-section comparison of BEIGF's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-05 vs the prior 10-Q · 2026-05-06
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +51 | −44 | ~23 | 25 |
| Market risk (Item 3) | Text added/removed | 0 | 0 | ~5 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 0 |
| Legal proceedings | Text added/removed | 0 | 0 | ~2 | 3 |
| Risk factors | Some risk factors updated | +1 | −1 | ~20 | 435 |
| Other information | Text added/removed | +3 | −3 | 0 | 2 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-05
On July 23, 2026, we announced a $300 million expansion of our flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell, New Jersey, to add small molecule manufacturing capabilities.
On June 30, 2026, we announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306) evaluating foundational Bruton’s tyrosine kinase (“BTK”) inhibitor BRUKINSA® plus rituximab versus bendamustine plus rituximab in adult patients with previously untreated mantle cell lymphoma (“MCL…
On May 13, 2026, we announced that the U.S. Food and Drug Administration (“FDA”) granted accelerated approval to BEQALZI™ (sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) MCL, after at least two lines of systemic the…
The following table summarizes our results of operations for the three and six months ended June 30, 2026 and 2025:
Total revenue increased to $1,705.1 million for the three months ended June 30, 2026, from $1,315.3 million for the three months ended June 30, 2025, due to increased sales of BRUKINSA, TEVIMBRA, as well as increased sales of in-licensed products from Amgen.
Text removed vs the prior filing · source: 10-Q · 2026-05-06
•Received Orphan Drug Designation in Japan for the treatment of adult patients with relapsed or refractory (“R/R”) marginal zone lymphoma (“MZL”).
•Submitted New Drug Application in Japan for R/R MZL and tablet formulation.
•Launched and commercially available in China for the treatment of adult patients with R/R mantle cell lymphoma (“MCL”) and R/R chronic lymphocytic leukemia (“CLL”)/small lymphocytic lymphoma (“SLL”).
•Included in the European Society of Medical Oncology (“ESMO”) guidelines as a recommended third-line treatment for R/R MCL patients.
•Received acceptance of a Supplemental Biologics License Application (“sBLA”) by the U.S. Food and Drug Administration (“FDA”) with Priority Review for the treatment of adult patients with first-line HER2-positive gastroesophageal adenocarcinoma (“GEA”) in combination with ZIIHERA (zanidatamab) and …
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-08-05
We are regularly under examination by tax authorities, including U.S. and non-U.S. tax authorities. The final resolution of any tax examinations could result in unanticipated increases in our tax expense and changes to the timing of required tax payments, which could affect our cash flows for any pa…
Text removed vs the prior filing · source: 10-Q · 2026-05-06
We are regularly under examination by tax authorities, including U.S. and non-U.S. tax authorities (PRC, Switzerland and other countries). The final resolution of any related administrative reviews or litigation could result in unanticipated increases in our tax expense and changes to the timing of …
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-05
Effective as of August 3, 2026, the Swiss Articles were amended to reflect changes in the Company’s total issued share capital resulting from the issuance to one of the Company’s wholly-owned subsidiaries of 866,073 of the Company’s fully paid-up registered shares with a nominal value of $0.0001 eac…
A copy of the Company’s amended Swiss Articles is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
Up to 9,353 ADSs plus up to such additional number of ADSs subject to restricted share units (“RSUs”) equal to the net number of ADSs resulting from applicable RSU vestings after sell-to-cover for withholding tax.
Text removed vs the prior filing · source: 10-Q · 2026-05-06
(Co-Founder, Chief Executive Officer, and Chairman of the Board of Directors)
(ii)up to such net number of ADSs to be received upon vesting of unvested RSUs in 2026 after sell-to-cover for withholding tax, to be sold by Mr. Oyler; and
(iii)up to 60,010 ADSs to be sold by the Pan-Oyler Foundation.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice